Abstract Bisphenol A (BPA) is an endocrine disrupting compound used in food and beverage plastic containers and has been shown to increase breast cancer cellular proliferation. However, the concentrations of BPA used in these experiments are far higher than the physiological levels of BPA detected in the human body. We observed in vitro that exposure of MCF-7 cells to physiological concentrations of BPA failed to increase cell proliferation or to induce canonical estrogen-responsive genes (pS2 and progesterone receptor (PR)), in contrast to 17β-estradiol (E2) treatment. However, MCF-7 cells treated with 10 nM BPA induced ALDH1 expression, a marker of human mammary stem cells. When treated with 10 nM BPA, mammospheres derived either from MCF-7 cells, a patient-derived xenograft, or the normal mouse mammary gland exhibited increased size; however, these effects were not observed in MDA-MB-231 mammospheres. Mechanistically, BPA induced SOX2 mRNA and protein in MCF-7 mammospheres, resulting from enhanced CREB phosphorylation, and subsequent binding of pCREB to a SOX2 downstream enhancer. These findings suggest that physiological levels of BPA increase estrogen receptorpositive breast cancer tumor maintenance through enhanced cancer stem-like cell activity via direct regulation of SOX2 transcription.
Introduction
Endocrine disruptors (EDCs) are exogenous chemicals that interfere with an aspect of hormone action [1] . Bisphenol A (BPA) is an EDC that has been shown to have effects in multiple tissues at multiple times during development [2] [3] [4] . BPA is present in food and drink packaging and other consumer products [4, 5] , and as a result, BPA is present at a low dose (approximately 1 ng/ml, which is equivalent to 4.38 nM) in most human tissues and fluids, including blood, breast milk, and urine [4, 6, 7] . BPA has estrogenic activity and its ability to compete with estradiol for binding to the estrogen receptors (ERs) has been shown [8] [9] [10] . Given the role of estrogens in human breast cancer etiology, endocrine-active chemicals that interfere with or modulate estrogen signaling are potential factors contributing to the high incidence of breast cancer.
Fetal exposure to BPA in mice and monkeys results in altered mammary gland development, such that mammary gland stroma and epithelium are transformed [11] [12] [13] [14] . In murine models, intraductal hyperplasia and ductal carcinoma in situ (DCIS) were observed after BPA exposure [14] [15] [16] [17] [18] [19] [20] . Besides the effects of BPA on fetal mammary gland development, BPA also effects ER-positive (ER + ) breast cancer cell lines, by increasing proliferation, inhibiting apoptosis, and inducing chemoresistance [21] [22] [23] [24] [25] [26] [27] [28] [29] .
It has been demonstrated that cells with cancer stem-like activity, including self-renewal potential, sustain the growth of breast tumors [30] [31] [32] and that MCF-7 mammospheres are enriched with cancer stem cells [33, 34] . The transcription factors OCT4, SOX2, and NANOG, which are master regulators of pluripotency in embryonic stem cells [35] [36] [37] , are also present in breast stem cells and function to maintain an undifferentiated state and to prevent differentiation [37, 38] . Of these factors, SOX2 is the only one detectable by immunohistochemical staining of breast tumors or mammospheres [39] . The objective of this study was to compare the effects of BPA and estrogen treatment on SOX2 expression in MCF-7 breast cancer stem cells.
Results
Exposure of MCF-7 Cells to Physiological Levels of BPA Does Not Induce Cell Proliferation or the Expression Canonical Estrogen-Responsive Genes It has been previously shown that treatment of MCF-7 cells with 1 μM BPA increases cell proliferation in an ERdependent mechanism by 96 h [21] . However, this magnitude of BPA exposure is approximately 1000-fold higher than the physiological levels of BPA present in most human tissues and fluids [6] . Therefore, we tested whether exposure of cells to a range of BPA concentrations (1 nM to 10 μM) would increase MCF-7 cell number, using 10 nM 17β-estradiol (E2) as a control. Whereas exposure to E2 increased the cell number 3-fold after 72 h, and exposure to 1 μM or 10 μM BPA increase proliferation >2-fold, neither 1 nor 10 nM of BPA treatment increased proliferation as compared to vehicle (Fig. 1a) . Longer exposure of cells to BPA did not increase cell proliferation, since 10 nM of BPA also failed to increase proliferation after a 1-week treatment ( Supplementary Fig. 1 ). We next tested whether Blow^levels of BPA treatment would be sufficient to induce expression of canonical estrogenresponsive genes. Whereas E2 treatment induced expression of pS2 (TFF1) and progesterone receptor (PR) messenger RNA (mRNA), 10 nM BPA was not sufficient to induce expression above levels observed with vehicle alone (Fig. 1b) .
BPA Increases Phosphorylated CREB in MCF-7 Cells
In addition to the classical E2 pathway, a growing body of evidence suggests that estrogens act through alternative pathways involving non-classical, membrane-associated estrogen receptors (mERs) [40] . Indeed, it has been demonstrated that CREB is phosphorylated and activated (phospho-CREB, pCREB) by low doses of E2 and BPA in pancreatic islet cells involving a non-classical mER [41] . The expression of total CREB and pCREB was measured in MCF-7 cells by immunoblotting. Treatment with either 10 nM E2 or 10 nM BPA induced phosphorylation of CREB (Fig. 1c) . Stimulation of pCREB by E2 or BPA was not observed in human MDA-MB-231 triple-negative breast cancer cells (Supplementary Fig. 2 ).
BPA Induces ALDH1 Expression in MCF-7 Cells and Increases Mammosphere Size
Breast cancer stem cells were first identified as a CD24 −/low / CD44 + population that have the ability to give rise to tumor growth when xenografted into immunocompromised mice [42] . Subsequent studies identified several other markers of cells with stem-like features, including aldehyde dehydrogenase 1 (ALDH1). ALDH1 + cells are found in several breast cancer cell lines that have enhanced tumor initiation ability when xenografted into immunocompromised mice [43] . MCF-7 cells treated with 10 nM BPA induced the expression of ALDH1 mRNA (Fig. 1d) [43] and ALDH1 protein expression (Fig. 1e) . In order to determine the effect of BPA treatment on MCF-7 breast cancer stem cell activity, MCF-7 cells were plated as single cells in stem cell culture conditions to form mammospheres. MCF-7 mammospheres are enriched in stem cells compared with adherent cells since mammosphere cells high express stem cell markers (NANOG, SOX2, and OCT4) ( Supplementary Fig. 3A ) and have self-renewal ability ( Supplementary Fig. 3B ). Mammosphere cultures were treated on days 4 and 7 with either ethanol (EtOH; control), 10 nM E2, or 10 nM BPA during mammosphere growth. After 10 days in culture, MCF-7 mammospheres treated with either E2 or 10 nM BPA were larger than mammospheres treated with vehicle (Fig. 2a) . Additional images are shown in Supplementary Fig. 4 . The largest mammospheres (150 μm in diameter) are found in cultures treated with E2 or BPA, but not in control cultures (Fig. 2b) . The increased mammosphere size was observed in cells isolated from an ER + breast tumor patient-derived xenograft (PDX). PDX mammospheres treated with 10 nM BPA were larger than mammospheres exposed to EtOH (Fig. 2c) .
BPA does not only increase the size of tumor-derived mammospheres but also increases the size of normal mammary gland mammospheres. Of the BPA, 10 nM led to bigger size spheres than those treated with EtOH (Fig. 2d ). E2-treated mammospheres are intermediate of those treated with EtOH and BPA.
BPA Induces SOX2 Stem Cell Marker Expression in MCF-7 Mammospheres but Not in MDA-MB-231 Mammospheres
SOX2, a transcription factor essential for maintaining selfrenewal and pluripotency, is expressed in MCF-7 mammospheres and promotes sphere formation [39] . Therefore, the effect of BPA treatment on SOX2 expression in MCF-7 cancer stem cells was analyzed. MCF-7 mammospheres were treated with either 1 or 10 nM of E2 or BPA for 10 days. Only 10 nM BPA was able to significantly induce SOX2 mRNA and protein expression, while 1 nM BPA and 1 or 10 nM E2 were not (Fig. 3a, b) .
Human MDA-MB-231 triple-negative breast cancer cells [44] also have the ability to be propagated in vitro as nona d h e r e n t m a m m o s p h e r e s [ 3 3 ] . U n l i k e M C F -7 mammospheres, MDA-MB-231 mammospheres treated with either 10 nM E2 or 10 nM BPA for 10 days in culture were similar in size as control-treated mammospheres (EtOH) (Fig. 4a) . Furthermore, neither E2 nor BPA exposure increased SOX2 expression in MDA-MB-231 mammospheres (Fig. 4a) .
BPA Induces Binding of pCREB to a Downstream Enhancer of SOX2 but Does Not Induce Expression of Canonical Estrogen-Responsive Genes in MCF-7 Cells
PR and pS2 are classical E2-induced target genes and are known to be responsive to E2 in MCF-7 cells. Whereas E2 treatment induced pS2 and PR expressions in MCF-7 cellderived mammospheres, treatment with 10 nM BPA did not ( Fig. 5 ), similar to our observations in adherent MCF-7 cells. Whereas E2 decreased ERα mRNA levels ( Fig. 5a ), as expected based on the known ERα transcriptional activation cycle [45] , BPA treatment had no effect on ERα mRNA levels ( Fig. 5b) .
Based on these results, potential non-genomic, ERdependent regulation of SOX2 expression was explored by measuring activation of CREB (pCREB). To determine whether BPA-activated pCREB directly regulates SOX2, ChIP was performed after a 5-min treatment with either E2 or BPA. pCREB was enriched at an enhancer region located 143 kb downstream of the SOX2 coding region only after BPA treatment (Fig. 6 ), which correlates with gene expression.
Discussion
Epidemiological, clinical, and experimental studies over more than a century confirm that estrogen is associated with the development of breast cancer. Increased exposure to estrogen, caused by early menarche, late menopause, high plasma Immunoblot analysis of SOX2 protein expression was normalized to β-actin protein estrogen levels, and menopausal hormone replacement therapy, is associated with an increased risk of breast cancer [46] .
BPA is considered a xenoestrogen since many studies have shown that it binds to, and/or activates, estrogen receptors [47, 48] . In vitro, BPA can bind to the estrogen receptor, increase estrogen-regulated gene expression, and increase cell growth in estrogen-sensitive human breast cancer cell lines [21] . However, in these studies, the concentration of BPA used was up to a thousand times greater (i.e., 1 μM) than the concentration of BPA measured in human serum (1-7 nM) [49, 50] . These experiments show clear differences between BPA and E2 in breast cancer cells (ALDH expression, SOX2 regulation, ERα target genes).
Extensive studies in vitro and in vivo have demonstrated that BPA has an effect in mammary gland tumorigenesis, since fetal exposure to BPA significantly increases pre-neoplastic lesions in rodents mammary glands, which are similar phenotypes to those observed in human breast carcinogenesis [18, 29, [51] [52] [53] . Clinical observations have shown that higher circulating serum BPA levels are also correlated with increased mammographic breast density [29, 54] . Taken together, the results of these studies suggest that BPA is likely to have significant effects on mammary epithelium and carcinogenesis. Therefore, studies focused on proliferation of already transformed and immortalized breast cancer cells do not adequately address the potential for malignant transformation from a benign state.
Breast tumors harbor a subset of cancer stem cells that have the ability to initiate and maintain tumorigenesis, as well as resist conventional anti-cancer therapies [55, 56] . Similar to normal breast stem cells, breast cancer stem cells possess the ability to generate highly proliferative cells, as well as more differentiated cancer cells representing several lineages that constitute the bulk of heterogeneous tumors [55] . Also, breast cancer stem cells are able to maintain stem-like properties (tumor initiation, self-renewal, and limited differentiation potential) while growing as spheres (mammospheres) in in vitro assays [33, 57] . It has been previously shown that 10 μM BPA, which increases MCF-7 cell proliferation, also increases MCF-7 mammosphere size [58] . Our studies are unique in that we are able to demonstrate that 10 nM BPA (1000 times less) does not induce MCF-7 cell proliferation but is sufficient to increase mammosphere size.
The transcription factors OCT4, SOX2, and NANOG are required to maintain the pluripotency and self-renewal in embryonic stem cells [35, 36] . Moreover, these pluripotency transcription factors are present in breast stem cells and help to maintain an undifferentiated state [38] . However, in breast cancer stem cells, pluripotency transcription factors are overexpressed [39, 55, 56] , which suggests the hypothesis that Baberrant expressions of OCT4, SOX2, and NANOG cause continuous activation of self-renewal leading to oncogenic transformation and tumor initiation and maintenance^ [37] . For example, SOX2 is overexpressed in gliomas and has an essential role in the initiation, maintenance, and recurrence of tumors [37, 59, 60] . Similarly, SOX2 is overexpressed in breast carcinomas [37, 61] and, in particular, in breast cancer stem cells relative to bulk tumor cells [39] . In this study, we showed that SOX2 expression can be induced in MCF-7 mammospheres treated with 10 nM BPA. These data suggest that SOX2 is a suitable marker to monitor the effect of BPA exposure in cancer stem cell phenotypes. In addition, SOX2 presents a novel therapeutic target for breast tumors. Ideally, therapeutic strategies to SOX2 would preferentially target cancer stem cells and could augment current clinically used frontline therapies. There is sufficient pre-clinical evidence that silencing of SOX2 gene expression in breast cancer cell lines reduces cell proliferation and colony formation and significantly reduces primary tumor growth [62] .
Despite the fact that normal mammary stem cells do not express ERα, it has been demonstrated that they respond to estrogen signaling [63, 64] . However, the mechanism of estrogen signaling in mammary stem cells remains unclear. MCF-7 mammospheres express ERα and estrogen regulates the ER-positive breast cancer stem/progenitor cells [65] .
It has also been proposed that BPA is an androgen receptor (AR) ligand that triggers anti-androgenic responses, although these data are controversial [66] . MDA-MB-231 mammospheres do not express ERα nor AR, and BPA has no effect on MDA-MB-231 mammosphere size or SOX2 expression. These data suggest that BPA may act via ERα or AR, or an independent pathway, to increase MCF-7 mammosphere size to regulate the phosphorylation of CREB and SOX2 expressions.
Classical E2-responsive genes are not upregulated in MCF-7 mammospheres treated with 10 nM BPA. However, E2 and BPA are able to activate a functional non-classical mER in the endocrine pancreas [67, 68] . Indeed, it is demonstrated that a low dose of BPA (1 nM) activates CREB (pCREB) in pancreatic islet cells involving a non-classical membrane estrogen receptor [41] . We demonstrated that 10 nM of BPA induced pCREB levels in MCF-7, but not in MDA-MB-231, cells. In addition, we showed that pCREB was recruited to an enhancer of SOX2 to induce SOX2 expression. These results point to a non-classical mER, or ERindependent signaling pathway, to mediate BPA activity in E2-dependent MCF-7 cells.
Overall, we have shown that low physiological levels of BPA increase ER + breast cancer tumor maintenance through enhanced cancer stem cell activity via regulation of SOX2 expression, which is activated by pCREB via mER. Based on this evidence, we predict that anti-estrogen treatments that are effective in ER-positive control of breast cancer cell Fig. 6 BPA induces pCREB recruitment to a SOX2 enhancer in MCF-7 cells. a An enhancer is located downstream of the SOX2 coding sequence. b MCF-7 cells were treated for 5 min with 10 nM E2, 10 nM BPA, or vehicle control. ChIP was performed using an antibody to pCREB and primers flanking the enhancer proliferation may not be effective in blocking BPA-dependent proliferation of cancer stem cells, which activates a nonclassical membrane estrogen receptor pathway. A therapy targeting SOX2 + breast cancer stem cells, which are able to sustain tumor growth, metastasis, and recurrence [69] [70] [71] , could be a novel approach to eradicate ER + breast cancers.
Materials and Methods
Reagents and Antibodies E2 and BPA were purchased from Sigma-Aldrich Corporation (St. Louis, MO, USA). SOX2 (clone D6D9), CREB (clone 48H2), pCREB (clone 87G3), and β-actin (#4967) antibodies were purchased from Cell Signaling Technology (Danvers, MA, USA). ALDH-1 antibody (clone 44/ALDH) was purchased from BD Biosciences (San Jose, CA). β-Tubulin antibody was purchased from Santa Cruz Biotechnology (clone H-235, Dallas, TX). Horseradish peroxidase-conjugated antirabbit and anti-mouse antibodies were purchased from Thermo Fisher Scientific (Waltham, MA, USA).
Cell Culture and Proliferation Assays
MCF-7 and MDA-MB-231 cells were obtained from ATCC and grown according to standard protocols, and cell lines were verified each year by STR profiling. All in vitro assays were performed using DMEM media without phenol red (Corning, Corning, NY, USA), supplemented with 5% charcoal dextran-treated fetal bovine serum (CDT-FBS) (Omega Scientific, Tarzana, CA, USA). MCF-7 cells were plated at 50,000 cells/ml in quadruplicate on day 1. On days 2 and 3, the media was changed to media without phenol red and with 5% CDT-FBS. On day 5, the cells were treated with either vehicle (0.1% EtOH), E2 (10 nM), or BPA (1-10 nM). For proliferation experiments on days 7 and 9, the media was refreshed, and on day 12, triplicate wells were counted by a hemocytometer. To analyze protein expression, the cells were harvested 15 min after treatment on day 5, and for RNA, the cells were harvested 24 h after treatment on day 5.
Mammosphere Assays
From Cell Lines To establish MCF-7 mammospheres, on day 1, cells were seeded onto ultralow attachment plates at 50,000 cells/ml and cultured in mammosphere medium (phenol-red free DMEM (Corning) supplemented with B27 (Invitrogen), 20 ng/ml EGF, 20 ng/ml bFGF (BD Biosciences, San Jose, CA, USA), and 4 μg/ml heparin (Sigma-Aldrich Corporation)). To establish mammospheres with MDA-MB-231 cells, cells were plated at a density of 250,000 cells/ml. On days 4 and 7, the mammospheres were treated with vehicle control (0.1% ethanol), E2 (10 nM), or BPA (10 nM). Treatments were performed in triplicate. The entire well was imaged on day 10 of hormone treatments, and the mammospheres were then collected for RNA or protein extraction. Sphere size was performed by counting spheres over 50 μm in size from images of each well.
To assess the self-renewal of the stem-like cells, mammospheres were dissociated in trypsin 1:3 (v/v) in mammosphere medium, and cells from first generation of mammospheres were seeded onto ultralow attachment plates and cultured 7 days in the mammosphere media to form second-generation mammospheres. + , infiltrating ductal carcinoma and intraductal lobular carcinoma, as described in [72] . A subline of HCI-7 cells was labeled with luciferase 2 (Luc2) as previously described [73] .
To generate HCI-7-Luc2 mammospheres, PDX tumors were collected and mechanically dissociated and digested (4 h, 37°C, 225 rpm) with 1.5 U/g collagenase A (Roche Diagnostics, Indianapolis, IN, USA) in 1.8-ml/g mammosphere medium. The resulting cell suspension was washed three times with ×1 PBS, 5 mM EDTA (Sigma), and 1% BSA (Santa Cruz, CA, USA) and then centrifuged (800g, 5 min). Red blood cells were then lysed with NH 4 Cl solution (Stem Cell Technologies, Vancouver, Canada), and samples were sieved through a 40-μm mesh. A single-cell suspension was obtained by passing the sample repeatedly through a 25-g needle. Mammospheres were grown using the same culture conditions as MCF-7 cells. Normal mammospheres were prepared from the mammary glands of 8-week-old FVB mice as described in [74] . On days 4 and 7, the mammospheres were treated with either vehicle control (0.1% EtOH), E2 (10 nM), or BPA (10 nM). Each experiment was performed at least three independent times, and treatments were performed in triplicate replicates. The entire well was imaged on day 10 of hormone treatments, and the mammospheres were then collected for RNA or protein extraction.
RNA and Quantitative PCR
Total cellular RNA was extracted from cells by using TRIzol Reagent (Invitrogen). Each RNA sample was collected in triplicate, and each PCR reaction was amplified in triplicate. Total RNA was converted to complementary DNA (cDNA) with Thermo Scientific Maxima First-Strand cDNA Synthesis Kit (Thermo Fisher Scientific) according to the manufacturer's instructions. cDNA was subjected to quantitative PCR using the Thermo Scientific Maxima SYBR Green qPCR Master Mix with ROX (Thermo Fisher Scientific). Gene expression levels were compared after normalization to endogenous β-actin (ACTB). Primers were selected using Primer-BLAST (https://www.ncbi.nlm.nih.gov/tools/primer-blast/), and the sequences used are (5′ to 3′) ACTB F GGACTTCG AGCAAGAGATGG, R AGCACTGTGTTGGCGTACAG; ALDH1 F GTTAGCTGATGCCGACTTGG, R CCCACTCT CAATGAGGTCAAG; ERα F GAATCTGCCAAGGA GACTCGC, R ACTGGTTGGTGGCTGGACAC; NANOG F CAAAGGCAAACAACCCACTT, R TCTGCTGG AGGCTGAGGTAT; OCT-4 F GGGCTCACCCTGGG GGTTCT, R CTGCTGGGCGATGTGGCTGA; PR F AAATCATTGCCAGGTTTTCG, R TGCCACATGGTAAG GCATAA; PS2 F TTGTGGTTTTCCTGGTGTCA, R CCGAGCTCTGGGACTAATCA; SOX2 F GGGGAAAG TAGTTTGCTGCC, R CGCCGCCGATGATTGTTATT; SOX2 enhancer F AAGGATCCTGGAAAGCAGGC, R GTTTCCTTGGAGGTGGGAGG; and ACTB promoter F CAGTGCCTAGGTCACCCACT, R AGAAGTCG CAGGACCACACT.
Immunoblot Analysis
For pCREB analysis, cells were cultured in serum-free media for 6 h, followed by a 15-min treatment with 10 nM E2 or BPA. Protein extracts were prepared by homogenizing cells on ice in RIPA buffer containing protease inhibitors. Protein concentrations were measured using the Bradford method. Samples (40 μg/lane) were boiled at 95°C for 10 min in sodium dodecyl sulfate (SDS) loading buffer (Boston BioProducts, Ashland, MA, USA), separated on 8% SDS-PAGE gels and transferred to a polyvinylidenedifluoride membrane according to manufacturers' protocols (Bio-Rad Laboratories, Hercules, CA, USA). After incubation with 5% BSA in TBST for 60 min, the membrane was incubated with primary antibodies at 4°C overnight. Membranes were washed three times for 10 min and incubated with horseradish peroxidase-conjugated anti-rabbit or anti-mouse antibodies for 1 h at room temperature. Blots were washed with TBST three times and developed with an ECL system (Thermo Fisher Scientific) according to the manufacturer's protocols.
Chromatin Immunoprecipitation
Cells were hormone deprived by culture for 3 days in phenol red-free medium (Invitrogen) supplemented with 5% CDT-FBS. Cells were treated with 10 nM E2, 10 nM BPA, or ethanol as a vehicle control for 5 min, and ChIP was performed as described [75, 76] . Immunoprecipitated DNA was amplified by quantitative PCR (qPCR). Each ChIP was performed with triplicate biological replicates. Percent of inputs were normalized to percent of inputs for ACTB promoter.
Statistical Analysis
All data are expressed as mean ± standard error of the mean. All analyses were performed using Prism software, and statistically significant values were determined by Student's t test (p < 0.05).
